Payment overview · 2025
General Payments
$147.58
7 reported records · 6 companies
Healthcare provider profile · identity verified
Javed Ahmad, MD
Allopathic & Osteopathic Physicians|Internal Medicine · INDIO, CA · NPI 1346354479
Verified facts
What the public records show
CMS Open Payments records show Javed Ahmad, MD received $147.58 in general payments during 2025 across 7 reported records.
Novo Nordisk Inc accounted for 30.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Lokelma by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $44.61 | 30.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $24.63 | 16.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $23.87 | 16.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.73 | 14.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.68 | 13.3% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $14.06 | 9.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $147.58 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $44.61 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $24.63 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $23.87 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $20.73 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $14.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 86 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
86 | 31 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
152 | 48 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
153 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 988 | 286 |
| Levothyroxine Sodium | Levothyroxine Sodium | 920 | 209 |
| Lisinopril | Lisinopril | 729 | 207 |
| Losartan Potassium | Losartan Potassium | 697 | 193 |
| Amlodipine Besylate | Amlodipine Besylate | 693 | 207 |
| Metformin Hcl | Metformin Hcl | 570 | 170 |
| Gabapentin | Gabapentin | 528 | 194 |
| Omeprazole | Omeprazole | 472 | 117 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 421 | 128 |
| Baclofen | Baclofen | 378 | 119 |
| Metoprolol Succinate | Metoprolol Succinate | 367 | 104 |
| Hydralazine Hcl | Hydralazine Hcl | 319 | 87 |
| Doxazosin Mesylate | Doxazosin Mesylate | 299 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 296 | 89 |
| Furosemide | Furosemide | 284 | 81 |
| Famotidine | Famotidine | 265 | 78 |
| Tamsulosin Hcl | Tamsulosin Hcl | 257 | 74 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 250 | 97 |
| Eliquis | Apixaban | 225 | 50 |
| Fluticasone Propionate | Fluticasone Propionate | 217 | 76 |
| Montelukast Sodium | Montelukast Sodium | 216 | 59 |
| Trazodone Hcl | Trazodone Hcl | 216 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 202 | 59 |
| Simvastatin | Simvastatin | 183 | 44 |
| Alendronate Sodium | Alendronate Sodium | 181 | 64 |
| Meloxicam | Meloxicam | 169 | 65 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 165 | 46 |
| Carvedilol | Carvedilol | 163 | 51 |
| Fenofibrate | Fenofibrate | 162 | 45 |
| Buspirone Hcl | Buspirone Hcl | 156 | 33 |
| Ozempic | Semaglutide | 153 | 26 |
| Jardiance | Empagliflozin | 152 | 48 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 146 | 63 |
| Clopidogrel | Clopidogrel Bisulfate | 138 | 41 |
| Potassium Chloride | Potassium Chloride | 138 | 33 |
| Glimepiride | Glimepiride | 136 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 136 | 43 |
| Ibuprofen | Ibuprofen | 131 | 50 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 127 | 64 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 124 | 30 |
| Clonidine Hcl | Clonidine Hcl | 123 | 50 |
| Sertraline Hcl | Sertraline Hcl | 118 | 33 |
| Glipizide | Glipizide | 117 | 29 |
| Meclizine Hcl | Meclizine Hcl | 102 | 39 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 92 | 75 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 88 | 30 |
| Diclofenac Potassium | Diclofenac Potassium | 87 | 29 |
| Donepezil Hcl | Donepezil Hcl | 86 | 25 |
| Farxiga | Dapagliflozin Propanediol | 86 | 31 |
| Levetiracetam | Levetiracetam | 80 | suppressed |
| Finasteride | Finasteride | 78 | 17 |
| Januvia | Sitagliptin Phosphate | 77 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 26 |
| Linzess | Linaclotide | 74 | 23 |
| Ezetimibe | Ezetimibe | 71 | 23 |
| Lactulose | Lactulose | 71 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 70 | 21 |
| Trulicity | Dulaglutide | 69 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 68 | 54 |
| Benazepril Hcl | Benazepril Hcl | 67 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 67 | 33 |
| Warfarin Sodium | Warfarin Sodium | 65 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 64 | 24 |
| Mirtazapine | Mirtazapine | 60 | 21 |
| Allopurinol | Allopurinol | 59 | 18 |
| Myrbetriq | Mirabegron | 58 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 11 |
| Sucralfate | Sucralfate | 48 | 14 |
| Vascepa | Icosapent Ethyl | 48 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 17 |
| Azithromycin | Azithromycin | 46 | 40 |
| Atenolol | Atenolol | 44 | 13 |
| Xarelto | Rivaroxaban | 44 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 35 |
| Ventolin Hfa | Albuterol Sulfate | 42 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 19 |
| Midodrine Hcl | Midodrine Hcl | 40 | suppressed |
| Lovastatin | Lovastatin | 38 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 37 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 37 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 36 | suppressed |
| Ketoconazole | Ketoconazole | 36 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 36 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 35 | 11 |
| Enalapril Maleate | Enalapril Maleate | 35 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 34 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Nystatin | Nystatin | 34 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Digoxin | Digoxin | 31 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 31 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 31 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | 11 |
| Glipizide Er | Glipizide | 29 | suppressed |
| Hydrocortisone | Hydrocortisone | 29 | 18 |
| Nortriptyline Hcl | Nortriptyline Hcl | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 29 | 11 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 27 | suppressed |
| Clonidine | Clonidine | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 25 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Prolia | Denosumab | 24 | 17 |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Procto-Med Hc | Hydrocortisone | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Budesonide | Budesonide | 19 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 16 |
| Scopolamine | Scopolamine | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 14 |
| Tramadol Hcl | Tramadol Hcl | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 16 | suppressed |
| Minoxidil | Minoxidil | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 13 | suppressed |
| Sodium Polystyrene Sulfonate | Sodium Polystyrene Sulfonate | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Norethindrone Acetate | Norethindrone Acetate | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 11 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $147.58 · 7 records | Novo Nordisk Inc | FARXIGA, GVOKE HYPOPEN, REXULTI, Wegovy, YUPELRI | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error